Exclusive: Akeso kept a low profile before Keytruda results. Now it has global ambition

Plus: Can Anne Wojcicki save 23andMe?

September 25, 2024 Check out STAT+

Sponsored By

Courtesy Akeso STAT+ | The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions Little-known Chinese biotech Akeso partnered with Summit Therapeutics on a lung cancer immunotherapy that rivals Merck's Keytruda By Jonathan Wosen STAT+ | Generic drug lobby taps former BIO exec as new CEO The group has been without an official leader since December 2022, even as challenges to the generics industry mount. By John Wilkerson and Rachel Cohrs Zhang STAT+ | Celldex drug reduces chronic hive activity, but patient discontinuations raise questions Phase 2 study of barzolvolimab against placebo in 200 patients found 71% clear of hives. Company will move to Phase 3 trial of potential Xolair competitor. By Andrew Joseph Illustration: Alex Hogan/STAT, photo: Milken STAT+ | Can Anne Wojcicki save 23andMe? Shares, which once traded at $13, now change hands at just 35 cents, and it's not yet clear whether the CEO will succeed in taking the company private. By Matthew Herper Ozempic linked to lower opioid overdose rate in those with diabetes, study shows The authors said the findings, while preliminary, suggest that Ozempic-type drugs "may have value in helping to prevent opioid overdoses." By Lev Facher STAT+ | Moderna is scolded by a U.K. trade group for offering kids $2,000 to participate in a Covid trial A U.K. trade group decided Moderna violated industry codes by failing to maintain high standards and bringing "discredit" upon the industry. By Ed Silverman Courtesy GEPA pictures How Special Olympics kickstarted the push for better disability data It started out with organizers bringing doctors to the stadium for routine exams including vision, hearing and dental screenings. By Timmy Broderick

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser